|
© 2004 American Academy of Neurology Medical Hypothesis Homocysteine and levodopaShould Parkinson disease patients receive preventative therapy?From the Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, Ontario, Canada. Address correspondence and reprint requests to Dr. Anthony E. Lang, Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital, 399 Bathurst Street, MP11, Toronto, Ontario, Canada M5T 2S8; e-mail: lang{at}uhnres.utoronto.ca Epidemiologic evidence has linked elevation of serum homocysteine to an increased risk of coronary artery disease, stroke, and dementia. An increase in homocysteine levels in Parkinson disease (PD) recently has been discovered. Although B vitamin status and genetic factors are important modifying influences determining the degree of this elevation, the main cause appears to be therapy with L-dopa. It has been suggested that breakdown of L-dopa by catechol-O-methyltransferase results in increased homocysteine formation. Therefore, there are reasons to suggest that management of PD may render patients at increased risk of stroke, heart disease, dementia, and even accelerated nigral degeneration. At present, no controlled prospective studies have evaluated this phenomenon, although they are ongoing.
Received January 31, 2004. Accepted in final form March 22, 2004. The authors have developed an investigator-initiated study (mentioned in the article) that has been funded by an unrestricted educational grant from Novartis. This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
